Skip to content

Author

Rosalie C. Sears

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

MYC targeted de novo binders impair tumor growth

A panel of de novo designed intracellular protein binders that target conserved functional regions of MYC with nanomolar affinity, remodel MYC complexes and interaction networks in cells, suppress proliferation across MYC-dependent cancer models, and are depleted from orthotopic pancreatic tumors in vivo are developed.

N. McNamara-Bordewick, Ke-Jia Wu, Yu-Long Su et al. · 0 citations
Open access Sep 2026

IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. Although major histocompatibility complex class II (MHC-II) is typically expressed by professional antigen-presenting cells, its regulation and significance in malignant PDAC cells remain un...

Can-Ping Chen, Yi Zhang, Xi Li et al. · 0 citations
Sep 2026

Abstract A029: Chromatin accessibility profiling of human pancreatic tumors reveals epigenetic features of malignant and stromal cell subtypes

Pancreatic ductal adenocarcinoma (PDAC) disease progression involves complex cell state transitions in both malignant and non-malignant populations within the tumor microenvironment. To uncover PDAC cell states and epigenetic features associated with clinical outcome, we profiled 40 tumor samples (33 primary tumors a...

Kevin Hawthorne, Motoyuki Tsuda, Jenny Eng et al. · 0 citations
Sep 2026

The post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma.

Overall, it is found that the post-transcriptional regulator HuR facilitates immune evasion in PDAC by constraining T-cell function, identifying HuR blockade as a promising therapeutic strategy in combination with immunotherapies.

Yi-Fei Guo, Jennifer M. Finan, Alexandra Q. Bartlett et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.